Journal
The oncologist
Publication Date
5-8-2023
Volume
28
Issue
5
First Page
425
Last Page
432
Document Type
Open Access Publication
DOI
10.1093/oncolo/oyad002
Rights and Permissions
Kimberly Perez, Anna M Chiarella, James M Cleary, Nora Horick, Colin Weekes, Thomas Abrams, Lawrence Blaszkowsky, Peter Enzinger, Marios Giannakis, Lipika Goyal, Jeffrey A Meyerhardt, Douglas Rubinson, Matthew B Yurgelun, Wolfram Goessling, Bruce J Giantonio, Lauren Brais, Victoria Germon, Danielle Stonely, Srivatsan Raghavan, Basil Bakir, Koushik Das, Jason R Pitarresi, Andrew J Aguirre, Michael Needle, Anil K Rustgi, Brian M Wolpin, Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer, The Oncologist, Volume 28, Issue 5, May 2023, Pages 425–432, https://doi.org/10.1093/oncolo/oyad002. https://academic.oup.com/oncolo/article/28/5/425/7046246?login=true. © The Author(s) 2023. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Recommended Citation
Perez, Kimberly; Das, Koushik; and et al., "Phase Ib and expansion study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with metastatic pancreatic cancer." The oncologist. 28, 5. 425 - 432. (2023).
https://digitalcommons.wustl.edu/oa_4/4702
